N,N- dicyclopropyl- 4- ((1,5- dimethyl- 1H- pyrazol- 3- yl)amino)- 6- ethyl- 1- methyl- 1,6- dihydroimidazo(4,5- d)pyrrolo(2,3b)pyridine- 7- carboxamide
has antineoplastic activity; structure in first source
Also Known As:
BMS-911543
Networked: 7
relevant articles (1 outcomes,
1 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
| 1. | Bekaii-Saab, Tanios:
1 article
(12/2015)
|
| 2. | Bloomston, Mark:
1 article
(12/2015)
|
| 3. | Elnaggar, Omar:
1 article
(12/2015)
|
| 4. | Komar, Hannah M:
1 article
(12/2015)
|
| 5. | Lesinski, Gregory B:
1 article
(12/2015)
|
| 6. | Ludwig, Thomas:
1 article
(12/2015)
|
| 7. | Mace, Thomas A:
1 article
(12/2015)
|
| 8. | Ostrowski, Michael C:
1 article
(12/2015)
|
| 9. | Pitarresi, Jason R:
1 article
(12/2015)
|
| 10. | Shakya, Reena:
1 article
(12/2015)
|
Related Diseases
| 1. | Neoplasms (Cancer)
|
| 2. | Primary Myelofibrosis (Myelosclerosis)
01/01/2023
- " Between October 2007 and July 2013, 183 Mayo Clinic patients (median age 65 years; 58% males) with high/intermediate risk myelofibrosis (MF) were enrolled in consecutive phase 1/2 JAK2 inhibitor (JAKi) clinical trials with momelotinib (n = 79), ruxolitinib (n = 50), fedratinib (n = 23) and BMS-911543 (n = 31). " 07/01/2023
- " This review includes the current status of JAKi treatment for myelofibrosis, mainly focusing on investigational JAKis; jaktinib, lestaurtinib, itacitinib, gandotinib, BMS-911543, ilginatinib, TQ05105, and flonoltinib maleate. "
|
| 3. | Pancreatic Neoplasms (Pancreatic Cancer)
|
| 4. | Myeloproliferative Disorders (Myeloproliferative Disorder)
|
|
Related Drugs and Biologics